361 related articles for article (PubMed ID: 21649792)
21. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
22. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
Fahrleitner-Pammer A; Dobnig H; Dimai HP; Holzer H; Benesch T; Borchhardt K; Cejka D; Haas M
Clin Nephrol; 2009 Jun; 71(6):652-9. PubMed ID: 19473634
[TBL] [Abstract][Full Text] [Related]
23. Bone mineral density of the spine and femur in early postmenopausal Turkish women with endemic skeletal fluorosis.
Yildiz M; Akdoğan M; Tamer N; Oral B
Calcif Tissue Int; 2003 Jun; 72(6):689-93. PubMed ID: 14562997
[TBL] [Abstract][Full Text] [Related]
24. Association between increased serum osteoprotegerin levels and improvement in bone mineral density after parathyroidectomy in hemodialysis patients.
Zheng CM; Chu P; Wu CC; Ma WY; Hung KC; Hsu YH; Lin YF; Diang LK; Lu KC
Tohoku J Exp Med; 2012 Jan; 226(1):19-27. PubMed ID: 22156488
[TBL] [Abstract][Full Text] [Related]
25. [Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease].
Kochetkova EA; Nevzorova VA; Maĭstrovskaia IuV; Massard G
Ter Arkh; 2010; 82(8):10-4. PubMed ID: 20873238
[TBL] [Abstract][Full Text] [Related]
26. Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.
Kim CS; Bae EH; Ma SK; Han SH; Choi KH; Lee J; Chae DW; Oh KH; Ahn C; Kim SW;
PLoS One; 2016; 11(11):e0166792. PubMed ID: 27855207
[TBL] [Abstract][Full Text] [Related]
27. News on biomarkers in CKD-MBD.
Mazzaferro S; Tartaglione L; Rotondi S; Bover J; Goldsmith D; Pasquali M
Semin Nephrol; 2014 Nov; 34(6):598-611. PubMed ID: 25498379
[TBL] [Abstract][Full Text] [Related]
28. [Kidney and bone update : the 5-year history and future of CKD-MBD. Bone metabolic marker in hemodialysis patients update].
Okuno S
Clin Calcium; 2012 Jul; 22(7):1009-17. PubMed ID: 22750933
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
30. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
31. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
[TBL] [Abstract][Full Text] [Related]
32. Sex steroids, biochemical markers, bone mineral density and histomorphometry in male osteoporosis patients.
Fassbender WJ; Balli M; Görtz B; Hinrichs B; Kaiser HE; Tracke HS
In Vivo; 2000; 14(5):611-8. PubMed ID: 11125545
[TBL] [Abstract][Full Text] [Related]
33. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
[TBL] [Abstract][Full Text] [Related]
34. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
36. Inverse Association Between Serum Osteoprotegerin and Bone Mineral Density in Renal Transplant Recipients.
Hsu BG; Chen YC; Ho GJ; Shih MH; Chou KC; Lin TY; Lee MC
Transplant Proc; 2016 Apr; 48(3):864-9. PubMed ID: 27234754
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting bone mineral density in elderly men receiving chronic in-center hemodialysis.
Eisenberg B; Tzamaloukas AH; Murata GH; Elliott TM; Jackson JE
Clin Nucl Med; 1991 Jan; 16(1):30-6. PubMed ID: 1999053
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
39. [Mineral and bone disturbances associated with chronic kidney disease].
Suchowierska E; Myśliwiec M
Pol Merkur Lekarski; 2010 Feb; 28(164):138-43. PubMed ID: 20369744
[TBL] [Abstract][Full Text] [Related]
40. Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study.
Yun HJ; Ryoo SR; Kim JE; Choi YJ; Park I; Shin GT; Kim H; Jeong JC
BMC Nephrol; 2020 Jul; 21(1):299. PubMed ID: 32711466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
